ReviewCurrent cardiology reports2009
Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes.
Review in Current cardiology reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Group IIA Secretory Phospholipase AArteriosclerosis, thrombosis, and vascular biology · 2019Trial
- Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.The Journal of biological chemistry · 2014Trial
- Modulation of Airway Expression of the Host Bactericidal Enzyme, sPLA2-IIA, by Bacterial Toxins.Toxins · 2023Review
- Single nucleotide polymorphisms of Interleukin - 4, Interleukin-18, FCRL3 and sPLA2IIa genes and their association in pathogenesis of endometriosis.Molecular biology reports · 2023Article
- On the present and future role of Lp-PLAArchives of medical science : AMS · 2021Article
- Risk Factors for Elevated Serum Lipopolysaccharide in Acute Dengue and Association with Clinical Disease Severity.Tropical medicine and infectious disease · 2020Article
- A Lipidomic Perspective of the Action of Group IIA Secreted Phospholipase ABiomolecules · 2020Article
- A Secreted Phospholipase AMolecules (Basel, Switzerland) · 2019Article
- Maslinic acid modulates secreted phospholipase A2-IIA (sPLA2-IIA)-mediated inflammatory effects in macrophage foam cells formation.Journal of biosciences · 2018Article
- Pathogenesis of vascular leak in dengue virus infection.Immunology · 2017Review
- Macrophages and Phospholipases at the Intersection between Inflammation and the Pathogenesis of HIV-1 Infection.International journal of molecular sciences · 2017Review
- Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury.Neural regeneration research · 2017Review
- Secretory phospholipase A2 in the pathogenesis of acute dengue infection.Immunity, inflammation and disease · 2017Article
- Discovery of AZD2716: A Novel Secreted Phospholipase AACS medicinal chemistry letters · 2016Article
- Epigenetic control of group V phospholipase A2 expression in human malignant cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Dysfunctional HDL and atherosclerotic cardiovascular disease.Nature reviews. Cardiology · 2016Review
- Anti-inflammatory therapies for atherosclerosis.Nature reviews. Cardiology · 2015Review
- Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.International journal of molecular sciences · 2013Article
- Eicosanoids in metabolic syndrome.Advances in pharmacology (San Diego, Calif.) · 2013Review
- Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.Chemical reviews · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secretory phospholipase A(2) (sPLA(2)) represents a class of enzymes that hydrolyze phospholipids from cellular membranes and lipoproteins, resulting in multifarious proatherogenic actions in the vessel wall. Proatherogenic actions of sPLA(2) involve lipoprotein remodeling that facilitates proteoglycan binding and formation of lipid aggregates that are rapidly internalized by tissue macrophages. The hydrolysis of phospholipids on cell membranes generates bioactive lipids and lipolipoproteins with increased oxidative susceptibility. These particles and other bioactive lipids activate inflammatory pathways in various cells of the vessel wall. Transgenic mice overexpressing groups IIA, V, and X have increased atherosclerosis formation, whereas mice deficient in these sPLA(2) isoenzymes have less atherosclerosis formation. In apolipoprotein E knockout mice fed an atherosclerotic diet, sPLA(2) inhibition with varespladib reduced atherosclerosis formation. The potential for sPLA(2) inhibitors for preventing cardiovascular events is being investigated.
Indexed as
Identifiers
19863869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.